Stock Track | Akero Therapeutics Soars 5.82% Pre-Market on Analyst Optimism for Efruxifermin Drug Candidate

Stock Track

Jan 28, 2025

Akero Therapeutics (AKRO) stock surged 5.82% in pre-market trading on Tuesday, fueled by analyst optimism following the release of promising late-stage trial data for the company's investigational drug efruxifermin.

Multiple analysts raised their price targets and reiterated Buy/Overweight ratings on AKRO, citing the positive 96-week results from the SYMMETRY trial evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH).

Notably, Morgan Stanley significantly increased its price target to $96 from $46, with analysts highlighting efruxifermin's potential to capture significant market share and achieve commercial success if approved. Analysts at Canaccord Genuity, Citigroup, and H.C. Wainwright also raised their price targets, maintaining Buy ratings on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1169264798"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169264798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169264798?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-28 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169264798","market":"us","top_or_hot":-1,"title":"Stock Track | Akero Therapeutics Soars 5.82% Pre-Market on Analyst Optimism for Efruxifermin Drug Candidate","media":"Stock Track","content":"<p>Akero Therapeutics (AKRO) stock surged 5.82% in pre-market trading on Tuesday, fueled by analyst optimism following the release of promising late-stage trial data for the company's investigational drug efruxifermin.</p>\n\n<p>Multiple analysts raised their price targets and reiterated Buy/Overweight ratings on AKRO, citing the positive 96-week results from the SYMMETRY trial evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH).</p>\n\n<p>Notably, Morgan Stanley significantly increased its price target to $96 from $46, with analysts highlighting efruxifermin's potential to capture significant market share and achieve commercial success if approved. Analysts at Canaccord Genuity, Citigroup, and H.C. Wainwright also raised their price targets, maintaining Buy ratings on the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Akero Therapeutics Soars 5.82% Pre-Market on Analyst Optimism for Efruxifermin Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Akero Therapeutics Soars 5.82% Pre-Market on Analyst Optimism for Efruxifermin Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-28 22:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Akero Therapeutics (AKRO) stock surged 5.82% in pre-market trading on Tuesday, fueled by analyst optimism following the release of promising late-stage trial data for the company's investigational drug efruxifermin.</p>\n\n<p>Multiple analysts raised their price targets and reiterated Buy/Overweight ratings on AKRO, citing the positive 96-week results from the SYMMETRY trial evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH).</p>\n\n<p>Notably, Morgan Stanley significantly increased its price target to $96 from $46, with analysts highlighting efruxifermin's potential to capture significant market share and achieve commercial success if approved. Analysts at Canaccord Genuity, Citigroup, and H.C. Wainwright also raised their price targets, maintaining Buy ratings on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKRO","symbol_name":"Akero Therapeutics","start_time":0,"source_url":"","article_id":"1169264798","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169264798","pubTimestamp":1738073430,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Akero Therapeutics  stock surged 5.82% in pre-market trading on Tuesday, fueled by analyst optimism following the release of promising late-stage trial data for the company's investigational drug efruxifermin.Multiple analysts raised their price targets and reiterated Buy/Overweight ratings on AKRO, citing the positive 96-week results from the SYMMETRY trial evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis .Notably, Morgan Stanley significantly increased its price targe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKRO":"Akero Therapeutics"},"translate_title":"由于分析师对Efruxifermin候选药物持乐观态度，Akero Therapeutics盘前飙升5.82%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1},"content_text":"Akero Therapeutics (AKRO) stock surged 5.82% in pre-market trading on Tuesday, fueled by analyst optimism following the release of promising late-stage trial data for the company's investigational drug efruxifermin.\nMultiple analysts raised their price targets and reiterated Buy/Overweight ratings on AKRO, citing the positive 96-week results from the SYMMETRY trial evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH).\nNotably, Morgan Stanley significantly increased its price target to $96 from $46, with analysts highlighting efruxifermin's potential to capture significant market share and achieve commercial success if approved. Analysts at Canaccord Genuity, Citigroup, and H.C. Wainwright also raised their price targets, maintaining Buy ratings on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}